Serina Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2018 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Serina Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2018 to Q2 2024.
  • Serina Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was $5.2M, a 544% increase year-over-year.
  • Serina Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$21.5M, a 705% decline year-over-year.
  • Serina Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$14.8M, a 41.5% decline from 2022.
  • Serina Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$10.5M, a 20.6% decline from 2021.
  • Serina Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$8.68M, a 20.2% increase from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$21.5M $5.2M +$4.4M +544% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-09
Q1 2024 -$25.9M -$9.44M -$11.1M -669% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-14
Q4 2023 -$14.8M -$11.9M -$9.17M -339% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-22
Q3 2023 -$5.64M -$5.4M -$2.97M -122% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-14
Q2 2023 -$2.67M $808K +$3.43M Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-09
Q1 2023 -$6.1M $1.66M +$4.36M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q4 2022 -$10.5M -$2.7M -$545K -25.3% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-22
Q3 2022 -$9.92M -$2.44M -$480K -24.6% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 -$9.44M -$2.62M -$144K -5.82% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 -$9.29M -$2.71M -$618K -29.6% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-12
Q4 2021 -$8.68M -$2.16M +$288K +11.8% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-31
Q3 2021 -$8.96M -$1.96M +$588K +23.1% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 -$9.55M -$2.47M +$215K +8% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-12
Q1 2021 -$9.77M -$2.09M +$1.1M +34.5% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-13
Q4 2020 -$10.9M -$2.45M +$265K +9.78% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-29
Q3 2020 -$11.1M -$2.54M +$678K +21% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 -$7.12M -$2.69M +$400K +12.9% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-13
Q2 2020 $2M +$5.09M May 28, 2020 Jun 2, 2020 10-Q 2022-11-10
Q1 2020 -$12.2M -$3.19M -$54K -1.72% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-17
Q4 2019 -$12.2M -$2.71M +$475K +14.9% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-31
Q3 2019 -$12.6M -$3.22M -$1.07M -49.7% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-16
Q2 2019 -$11.6M -$3.09M -$1.16M -60.1% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-14
Q1 2019 -$10.4M -$3.13M -$2.9M -1233% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-14
Q4 2018 -$7.5M -$3.19M Oct 1, 2018 Dec 31, 2018 10-K/A 2020-03-31
Q3 2018 -$2.15M Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-14
Q2 2018 -$1.93M Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-14
Q1 2018 -$235K Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.